Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -212.1%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $47M | $51M | $3M | $5M | $10M | — | — | — |
| Enterprise Value | $40M | $44M | $5M | $2M | $6M | — | — | — |
| P/E Ratio → | -0.10 | — | — | — | — | — | — | — |
| P/S Ratio | 230.15 | 251.67 | — | — | — | — | — | — |
| P/B Ratio | 0.11 | 0.19 | 1.30 | 0.68 | 1.02 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 215.92 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -202.5% | -202.5% | — | — | — | — | — | — |
| Operating Margin | -6512.1% | -6512.1% | — | — | — | — | — | — |
| Net Profit Margin | -138400.0% | -138400.0% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -212.1% | -212.1% | -187.2% | -112.0% | -72.6% | -177.1% | -174.4% | -366.5% |
| ROA | -204.4% | -204.4% | -97.3% | -83.3% | -52.3% | -114.7% | -162.2% | -310.8% |
| ROIC | -7.6% | -7.6% | -120.0% | -146.2% | -167.5% | -250.1% | -1315.7% | — |
| ROCE | -10.0% | -10.0% | -153.7% | -113.0% | -134.8% | -170.8% | -173.4% | -367.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 1.89 | — | — | 0.22 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.03 | 1.45 | -0.38 | -0.43 | -0.25 | -0.84 | -1.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -647.82 | -647.82 | -4.47 | — | -2.51 | -26.84 | — | — |
Net cash position: cash ($10M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | 2.39 | 0.61 | 1.31 | 2.20 | 0.58 | 18.18 | 6.32 |
| Quick Ratio | 2.25 | 2.25 | 0.25 | 0.85 | 2.11 | 0.54 | 18.18 | 6.32 |
| Cash Ratio | 2.21 | 2.21 | 0.17 | 0.82 | 2.08 | 0.53 | 17.68 | 6.32 |
| Asset Turnover | — | 0.00 | — | — | — | — | — | — |
| Inventory Turnover | 0.96 | 0.96 | 0.41 | 0.52 | 3.52 | 0.24 | — | — |
| Days Sales Outstanding | — | 1273.10 | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $25M | $4187 | $1974 | $1227 | $1389 | $1389 | $1389 |
Capital exhaustion and dilution
As reported in recent financial filings, the company's P/S ratio of 219.78 suggests a valuation that is entirely detached from current revenue generation, reflecting speculative market pricing rather than any fundamental assessment of the firm's ability to scale its proprietary safety syringe technology into a viable commercial enterprise.
The extreme P/S multiple indicates that investors are pricing the company as a venture-stage asset rather than a traditional medical device manufacturer. This valuation appears to rely on the potential for future market disruption rather than current earnings, which remain deeply negative and provide no anchor for standard valuation metrics like P/E or EV/EBITDA.
Based on the company's reported figures, the gross margin of -202.49% highlights a severe inability to absorb fixed manufacturing overhead, suggesting that the current production scale is insufficient to achieve the unit-level profitability required to compete with established industry incumbents like Becton Dickinson in the medical instrument sector.
The negative gross margin suggests that the cost of goods sold currently exceeds revenue by a factor of two, which is characteristic of a pre-scale entity struggling with under-absorption of manufacturing overhead. Without a significant increase in production volume, these margins appear structurally unsustainable and indicate that the company is currently losing money on every unit sold.
As evidenced by the highly volatile cash conversion cycle, which reached 1041 days in 2025Q3, the company's working capital management appears severely strained, suggesting significant friction in converting inventory into cash compared to the more streamlined operations typically observed in established medical device manufacturing peers.
The extreme fluctuations in DSO and DIO metrics suggest that the company is struggling to manage its supply chain and customer collections effectively. This inefficiency likely exacerbates the firm's cash burn, as capital remains tied up in inventory and receivables for extended periods, further limiting the company's operational flexibility.
Based on the company's reported figures, the current ratio of 8.28 in 2026Q1 masks a precarious cash position, as the firm's cash reserves are being rapidly depleted by persistent operating losses and a lack of meaningful revenue generation to offset the ongoing burn rate of the business.
While the current ratio appears high, it is likely inflated by the presence of inventory that may not be easily liquidated at book value. Investors should monitor the rate of cash depletion closely, as the current burn rate suggests that the company's liquidity runway is narrowing significantly without a clear path to self-funding.
According to standard financial analysis, the P/S ratio is the most commonly misapplied metric for this business model, as it obscures the company's lack of commercial traction and fails to account for the massive, non-recurring costs associated with early-stage medical device manufacturing and regulatory compliance.
Using revenue multiples for a company in the pilot phase of commercialization can lead to a dangerous overestimation of value. A more appropriate focus would be on the 'cash burn per unit of revenue' or 'runway to commercial break-even,' which better capture the existential risks inherent in the firm's current financial structure.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying STSS stock.
Sharps Technology, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Sharps Technology, Inc.'s return on equity (ROE) is -212.1%. The historical average is -186.0%.
Based on historical data, Sharps Technology, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Sharps Technology, Inc. has -202.5% gross margin and -6512.1% operating margin.